H5

Hikma Pharmaceuticals PLCMUN Hikma Pharmaceuticals Stock Report

Last reporting period 31 Dec, 2023

Updated —

Last price

Market cap $B

5.52

Middle

Exchange

XMUN - Boerse Muenchen

View Section: Company Analysis

Hikma Pharmaceuticals Rating

H5

H5P.MU stock rating score is 58/100. Hikma Pharmaceuticals is aSomewhat Risky Investment.

The in-depth assessment covers such aspects as the profitability and solvency of the company, management efficiency, and growth sustainability. Our rating serves as an answer to whether the company`s shares are generally reasonable for purchase. The higher company rating score is, the more stock is attractive for investment.

Eyestock Rating

Last update 09.04.2024

58/100

Moderate score

Rating Breakdown

  • Profitability score

    25

    /25

  • Solvency score

    16

    /25

  • Efficiency score

    13

    /25

  • Stability score

    4

    /25

Hikma Pharmaceuticals PLC Rewards and Warnings

The assessment of the quality of a business is based on quantitative analysis of 10 key financials taken from the company's statements. Pay close attention to the cons, if any, before making a decision.

Financial

Check

Value

Net Profit Margin

7 %

Earnings quality

320 %

Gross Margin

49 %

Hikma Pharmaceuticals PLC's Historical Rating

How has the company's valuation changed in the past?

A quick analysis will help you understand how stable financial indicators are overall.


Growth Rates:
1 yearN/A
3 yearsN/A
5 yearsN/A

Discover High-rated Companies


View Section: Valuation